These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25451224)

  • 1. miR-25 alleviates polyQ-mediated cytotoxicity by silencing ATXN3.
    Huang F; Zhang L; Long Z; Chen Z; Hou X; Wang C; Peng H; Wang J; Li J; Duan R; Xia K; Chuang DM; Tang B; Jiang H
    FEBS Lett; 2014 Dec; 588(24):4791-8. PubMed ID: 25451224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of miR-25 and miR-181 Family Members Correlates with Reduced Expression of ATXN3 in Lymphocytes from SCA3 Patients.
    Krauss S; Nalavade R; Weber S; Carter K; Evert BO
    Microrna; 2019; 8(1):76-85. PubMed ID: 30147021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice.
    Rodríguez-Lebrón E; Costa Mdo C; Luna-Cancalon K; Peron TM; Fischer S; Boudreau RL; Davidson BL; Paulson HL
    Mol Ther; 2013 Oct; 21(10):1909-18. PubMed ID: 23820820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
    PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
    Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
    PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Variation in ATXN3 (Ataxin-3) 3'UTR: Insights into the Downstream Regulatory Elements of the Causative Gene of Machado-Joseph Disease/Spinocerebellar Ataxia Type 3.
    Melo ARV; Raposo M; Ventura M; Martins S; Pavão S; Alonso I; Bettencourt C; Lima M
    Cerebellum; 2023 Feb; 22(1):37-45. PubMed ID: 35034258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward understanding Machado-Joseph disease.
    Costa Mdo C; Paulson HL
    Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
    Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
    Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3.
    Chen ZS; Huang X; Talbot K; Chan HYE
    Cell Death Dis; 2021 Feb; 12(2):136. PubMed ID: 33542212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
    Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3.
    Koike Y; Jansen-West KR; Hanna Al-Shaikh R; Carlomagno Y; Song Y; Dunmore JA; LeDoux MS; Friedman JH; Pena AB; Uitti RJ; Zaremba J; van Gerpen JA; Pfeiffer RF; Veerappan V; Aiba I; Hashimoto R; Giles SS; Shah JS; Tipton PW; Huang JF; Wierenga KJ; Aasly J; Fryer JD; Petrucelli L; Wszolek ZK; Prudencio M
    Parkinsonism Relat Disord; 2021 Aug; 89():151-154. PubMed ID: 34303201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood and cerebellar abundance of ATXN3 splice variants in spinocerebellar ataxia type 3/Machado-Joseph disease.
    Raposo M; Hübener-Schmid J; Tagett R; Ferreira AF; Vieira Melo AR; Vasconcelos J; Pires P; Kay T; Garcia-Moreno H; Giunti P; Santana MM; Pereira de Almeida L; Infante J; van de Warrenburg BP; de Vries JJ; Faber J; Klockgether T; Casadei N; Admard J; Schöls L; Riess O; ; Costa MDC; Lima M
    Neurobiol Dis; 2024 Apr; 193():106456. PubMed ID: 38423193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the mammalian DNA end-processing enzyme polynucleotide kinase 3'-phosphatase in spinocerebellar ataxia type 3 pathogenesis.
    Chatterjee A; Saha S; Chakraborty A; Silva-Fernandes A; Mandal SM; Neves-Carvalho A; Liu Y; Pandita RK; Hegde ML; Hegde PM; Boldogh I; Ashizawa T; Koeppen AH; Pandita TK; Maciel P; Sarkar PS; Hazra TK
    PLoS Genet; 2015 Jan; 11(1):e1004749. PubMed ID: 25633985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machado-Joseph disease/spinocerebellar ataxia type 3.
    Paulson H
    Handb Clin Neurol; 2012; 103():437-49. PubMed ID: 21827905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3.
    Araujo J; Breuer P; Dieringer S; Krauss S; Dorn S; Zimmermann K; Pfeifer A; Klockgether T; Wuellner U; Evert BO
    Hum Mol Genet; 2011 Aug; 20(15):2928-41. PubMed ID: 21536589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
    Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
    Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity.
    Zhou YF; Liao SS; Luo YY; Tang JG; Wang JL; Lei LF; Chi JW; Du J; Jiang H; Xia K; Tang BS; Shen L
    PLoS One; 2013; 8(1):e54214. PubMed ID: 23382880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.